The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells

被引：14

作者：

Freddie, CT ^{[1
]}

Larsen, SS ^{[1
]}

Bartholomæussen, M ^{[1
]}

Lykkesfeldt, AE ^{[1
]}

机构：

[1] Danish Canc Soc, Inst Canc Biol, Dept Tumor Endocrinol, DK-2100 Copenhagen O, Denmark

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2004年 / 219卷 / 1-2期

关键词：

breast cancer; Arzoxifene; LY353381; LY335562; growth inhibition; gene expression;

D O I：

10.1016/j.mce.2004.02.003

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The benzothiophene arzoxifene is a new 3rd generation selective estrogen receptor (ER) modulator (SERM). We have investigated the effect of arzoxifene on growth and gene expression in the estrogen receptor a (ERalpha) positive human breast cancercell line MCF-7. Arzoxifene inhibits cell growth as effectively as the antiestrogen tamoxifen. Northern analysis revealed that arzoxifene exerts a statistically significant inhibition of pS2 and progesterone receptor B mRNA expression. Significant agonistic effect was observed on the antitrypsin mRNA expression. In contrast to estradiol and tamoxifen, arzoxifene does not upregulate cathepsin D mRNA and protein expression. The metabolite of arzoxifene (ARZm) is a more potent growth inhibitor of MCF-7 cells than arzoxifene. A tamoxifen resistant MCF-7 subline displayed a significant dose-dependent growth inhibition to ARZm, whereas an ICI 182,780 resistant cell line only responded to high concentration. Our results indicate that arzoxifene and especially ARZm are efficient growth inhibitors of ER positive human breast cancer cells, including tamoxifen resistant cells. Moreover, arzoxifene displays less estrogen agonistic effects in MCF-7 cells than tamoxifen. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：27 / 36

页数：10

共 52 条

[1] THE ANTIPROLIFERATIVE EFFECT OF TAMOXIFEN IN BREAST-CANCER CELLS - MEDIATION BY THE ESTROGEN-RECEPTOR [J].

BARDON, S ;

VIGNON, F ;

DEROCQ, D ;

ROCHEFORT, H .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1984, 35 (2-3) :89-96

[2]

BRIAND P, 1984, CANCER RES, V44, P1114

[3] Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Iα [J].

Brockdorff, BL ;

Heiberg, I ;

Lykkesfeldt, AE .

[4] ACTIVATION OF PS2 GENE-TRANSCRIPTION IS A PRIMARY RESPONSE TO ESTROGEN IN THE HUMAN-BREAST CANCER CELL-LINE MCF-7 [J].

BROWN, AMC ;

JELTSCH, JM ;

ROBERTS, M ;

CHAMBON, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (20) :6344-6348

[5] Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer [J].

Buzdar, A ;

O'Shaughnessy, JA ;

Booser, DJ ;

Pippen, JE ;

Jones, SE ;

Munster, PN ;

Peterson, P ;

Melemed, AS ;

Winer, E ;

Hudis, C .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1007-1014

[6] Endocrine therapy in the treatment of metastatic breast cancer [J].

Buzdar, AU .

SEMINARS IN ONCOLOGY, 2001, 28 (03) :291-304

[7]

Dardes RC, 2001, CLIN CANCER RES, V7, P4149

[8]

DATI C, 1990, ONCOGENE, V5, P1001

[9] Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens [J].

de Cremoux, P ;

Tran-Perennou, C ;

Brockdorff, BL ;

Boudou, E ;

Brünner, N ;

Magdelénat, H ;

Lykkesfeldt, AE .

[10]

Detre S, 2003, CANCER RES, V63, P6516

← 1 2 3 4 5 6 →